Yan Zhang Yaping Qin Hongen Xu Qihui Yao Yalan Gao Yushu Feng Jingli Ren
10.3389/pore.2021.637745
Pathol Oncol Res
2021 Apr 1;27:637745.
alk-rearranged adenocarcinoma pd-l1 alectinib histological transformation squamous cell carcinoma
CC BY
https://pubmed.ncbi.nlm.nih.gov/34257603/
Adenocarcinoma of Lung / drug therapy Anaplastic Lymphoma Kinase / genetics B7-H1 Antigen / metabolism Carbazoles / adverse effects Carcinoma, Squamous Cell / pathology Gene Rearrangement Lung Neoplasms / drug therapy Piperidines / adverse effects
Adenocarcinoma of Lung / drug therapy Anaplastic Lymphoma Kinase / genetics B7-H1 Antigen / metabolism Carbazoles / adverse effects Carcinoma, Squamous Cell / pathology Gene Rearrangement Lung Neoplasms / drug therapy Piperidines / adverse effects Case Reports Adenocarcinoma of Lung / genetics Adenocarcinoma of Lung / pathology B7-H1 Antigen / genetics Carcinoma, Squamous Cell / chemically induced Humans Lung Neoplasms / genetics Lung Neoplasms / pathology Male Middle Aged Prognosis Protein Kinase Inhibitors / adverse effects B7-H1 Antigen CD274 protein, human Carbazoles Piperidines Protein Kinase Inhibitors ALK protein, human Anaplastic Lymphoma Kinase alectinib
PMC8262189
34257603
Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib
2021